Generalized eruptive keratoacanthoma (Grzybowski variant).
We describe a patient with generalized eruptive keratoacanthoma (KA) of Grzybowski showing the characteristic features of this extremely rare condition. Since the first description by Grzybowski in 1950, only 28 additional cases (including the present one) have been reported. This variety of KA most commonly affects patients during the fifth to seventh decade of life and appears as a generalized eruption of hundreds to thousands of follicular papules. The small pruriginous papules often have a keratotic centre and show microscopic features of KA. Marked facial involvement is characteristic and can lead to masked facies with ectropion, as in our patient. The course of the disease is chronic and the response to therapy is poor.
Consigli
J E
JE
Department of Dermatology, Córdoba Hospital, Córdoba, Argentina. consigli@arnet.com.ar
González
M E
ME
Morsino
R
R
Guidi
A
A
Chappuis
J M
JM
Papa
M
M
Maldonado
S
S
D017255:Acitretin / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000627:therapeutic use; D019066:Facies; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D007636:Keratoacanthoma / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D011701:PUVA Therapy / Q000379:methods; D011994:Recombinant Proteins; D017444:Skin Diseases, Papulosquamous / Q000188:drug therapy / Q000473:pathology*; D017211:Treatment Failure
D003879:Dermatologic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D017255:Acitretin; D008727:Methotrexate